Posts

Early treatment with ocrelizumab lowers 5-year brain atrophy-rates in MS

Early treatment with ocrelizumab lowers 5-year brain atrophy rates in MS

Relapsing multiple sclerosis (MS) patients initiating ocrelizumab (Ocrevus®, Roche/Genentech) two years earlier had significant reductions in 5-year brain atrophy rates when compared to those switching from interferon β-1a, as reported in the latest results from the OPERA studies’ extension phase.